James A Ndako1, Obinna O Nwankiti2, Joy O Olorundare1, Stephen K S Ojo3, Charles E Okolie1, Oludolapo Olatinsu1, Victor T Dojumo4. 1. Department of Microbiology, Landmark University, Omu-Aran, Nigeria. 2. Department of Viral Research, National Veterinary Research Institute, Vom, Nigeria. 3. Department of Microbiology, Federal University, Oye-Ekiti, Nigeria. 4. Department of Medical Laboratory Services, Landmark University Medical Center, Omu-Aran, Nigeria.
Abstract
BACKGROUND: Hepatitis B infection is a public health concern globally. HBV can be associated with type II diabetes mellitus, as HBV outbreaks have been observed among diabetics in healthcare facilities. This study evaluates the prevalence of HBV infection among patients with type II diabetes mellitus. METHOD: A total of one hundred and eighty (180) diabetic patients and one-hundred non-diabetics (Controls) were recruited for this study. Structured questionnaires were administered to the consented participants to obtain relevant data. Sera samples obtained were screened using the HBsAg ELISA kit; CTK Biotech, Inc, while the 5 panel kit-rapid diagnostic test, was used to assay for serological markers. Questionnaires were used to obtain relevant information and demographic data. RESULT: Overall prevalence of HBV infection among diabetes patients was 13.3%. Breakdown showed 9 (5.0%) seropositivity was obtained among male subjects compared to 15(8.3%) recorded among the females, P = .834; P < .05. Subjects aged 41-50 years recorded, 7(3.9%) positivity P = .774; P > .05. Educational status of participants showed 22 (12.2%) positivity among subjects with tertiary level of education P = .032; P < .05). Risk factors considered showed that 5(2.8%).seropositive subjects were alcoholic consumers (P value = .9711; P > .05). Result among non-diabetics (Control) subjects showed (4%) seropositivity among the male subjects compared to (5.0%) seropositivity recorded among the female subjects (P = .739; P > .05). CONCLUSION: There is an indication of higher risk of HBV infection among type 2 diabetic patients when compared to non-diabetics. There is the need for more research on this area of study, to further validate the association between HBV infection and Diabetes Mellitus.
BACKGROUND:Hepatitis B infection is a public health concern globally. HBV can be associated with type II diabetes mellitus, as HBV outbreaks have been observed among diabetics in healthcare facilities. This study evaluates the prevalence of HBV infection among patients with type II diabetes mellitus. METHOD: A total of one hundred and eighty (180) diabeticpatients and one-hundred non-diabetics (Controls) were recruited for this study. Structured questionnaires were administered to the consented participants to obtain relevant data. Sera samples obtained were screened using the HBsAg ELISA kit; CTK Biotech, Inc, while the 5 panel kit-rapid diagnostic test, was used to assay for serological markers. Questionnaires were used to obtain relevant information and demographic data. RESULT: Overall prevalence of HBV infection among diabetespatients was 13.3%. Breakdown showed 9 (5.0%) seropositivity was obtained among male subjects compared to 15(8.3%) recorded among the females, P = .834; P < .05. Subjects aged 41-50 years recorded, 7(3.9%) positivity P = .774; P > .05. Educational status of participants showed 22 (12.2%) positivity among subjects with tertiary level of education P = .032; P < .05). Risk factors considered showed that 5(2.8%).seropositive subjects were alcoholic consumers (P value = .9711; P > .05). Result among non-diabetics (Control) subjects showed (4%) seropositivity among the male subjects compared to (5.0%) seropositivity recorded among the female subjects (P = .739; P > .05). CONCLUSION: There is an indication of higher risk of HBV infection among type 2 diabeticpatients when compared to non-diabetics. There is the need for more research on this area of study, to further validate the association between HBV infection and Diabetes Mellitus.
Authors: James A Ndako; Obinna O Nwankiti; Joy O Olorundare; Stephen K S Ojo; Charles E Okolie; Oludolapo Olatinsu; Victor T Dojumo Journal: J Clin Lab Anal Date: 2021-01-07 Impact factor: 2.352
Authors: Adebola T Olayinka; Akin Oyemakinde; Muhammad S Balogun; Anthonia Ajudua; Patrick Nguku; Moses Aderinola; Abiodun Egwuenu-Oladejo; Simeon W Ajisegiri; Samuel Sha'aibu; Bolanle O P Musa; Saheed Gidado; Abdulsalami Nasidi Journal: Am J Trop Med Hyg Date: 2016-08-15 Impact factor: 2.345
Authors: G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis Journal: Am J Public Health Date: 1999-01 Impact factor: 9.308
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Mariel M Finucane; Gretchen A Stevens; Melanie J Cowan; Goodarz Danaei; John K Lin; Christopher J Paciorek; Gitanjali M Singh; Hialy R Gutierrez; Yuan Lu; Adil N Bahalim; Farshad Farzadfar; Leanne M Riley; Majid Ezzati Journal: Lancet Date: 2011-02-03 Impact factor: 79.321
Authors: James A Ndako; Obinna O Nwankiti; Joy O Olorundare; Stephen K S Ojo; Charles E Okolie; Oludolapo Olatinsu; Victor T Dojumo Journal: J Clin Lab Anal Date: 2021-01-07 Impact factor: 2.352
Authors: Eric Lontchi-Yimagou; Charly Feutseu; Sebastien Kenmoe; Alexandra Lindsey Djomkam Zune; Solange Fai Kinyuy Ekali; Jean Louis Nguewa; Siméon Pierre Choukem; Jean Claude Mbanya; Jean Francois Gautier; Eugene Sobngwi Journal: Sci Rep Date: 2021-04-26 Impact factor: 4.379